Advances in Primary Biliary Cholangitis: Real-World Therapeutics, Biomarkers, and Patient-Centered Outcomes
Nov
2026
Description
This session reviews real-world and trial data on PBC therapeutics — including elafibranor, seladelpar, and linerixibat — alongside emerging biomarkers and digital tools for tracking pruritus and disease activity.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 1B
Elafibranor Versus Seladelpar in UDCA-Treated Primary Biliary Cholangitis: A 111-Health-System Propensity-Matched Comparative Effectiveness Study
Mohammad Alabbas, M.D | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 1B
Real-World Efficacy of Elafibranor in patients with Primary Biliary Cholangitis: Experience from a community-based hepatology practice
Rida Nadeem, MD | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - Bluebird Ballroom 1B
Serum IgM as a Prognostic Biomarker Linked to Intrahepatic Immune Activation in Primary Biliary Cholangitis: Insights from Histopathology and Single-cell Analysis
Taiki Okumura, MD | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - Bluebird Ballroom 1B
Improved modulation of pruritic and pharmacodynamic biomarkers with linerixibat added to a stable background of bile acid binding resins or peroxisome proliferator-activated receptor agonists in GLISTEN
Andreas E. Kremer, MD, PhD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - Bluebird Ballroom 1B
First-in-disease objective assessment of scratch and sleep patterns using a wearable digital health tool in primary biliary cholangitis: The LUMINARIA study
Cynthia Levy, MD, FAASLD | Abstract Presenter
